News

CLINUVEL
Posted by CLINUVEL
June 3, 2021

CLINUVEL Communiqué III

Dear shareholders, friends, INTRODUCTION During the lockdowns our team has had plenty...

Read More
CLINUVEL
Posted by CLINUVEL
June 1, 2021

Appendix 3Y Change of Director's Interest Notice

Information or documents not available now must be given to ASX as...

Read More
CLINUVEL
Posted by CLINUVEL
May 31, 2021

Chairman's Letter II

31 MAY 2021 Update during 2021 In a year with many ups...

Read More
CLINUVEL.
Posted by CLINUVEL.
May 21, 2021
CLINUVEL
Posted by CLINUVEL
April 29, 2021

Appendix 4C & Activity Report

Melbourne, Australia, 29 April 2021 CLINUVEL PHARMACEUTICALS LTD today announced its Appendix...

Read More
CLINUVEL
Posted by CLINUVEL
April 26, 2021

Wilsons Initiates Research Coverage of CLINUVEL

Melbourne, Australia, 26 April 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
April 11, 2021

CLINUVEL Strategic Update II

Melbourne, Australia, 12 April 2021 CLINUVEL today announced its second Strategic Update,...

Read More
CLINUVEL.
Posted by CLINUVEL.
April 6, 2021

CLINUVEL Kommuniqué II

Liebe Aktionäre, Freunde Wir begrüßen viele neue Aktionäre, insbesondere die große Anzahl...

Read More
CLINUVEL
Posted by CLINUVEL
April 1, 2021

CLINUVEL Communiqué II

Dear shareholders, friends We welcome many new shareholders, especially the large number...

Read More
CLINUVEL
Posted by CLINUVEL
March 31, 2021

Chair's Letter I

Direction and horizon In the last weeks, I have had investor questions...

Read More
CLINUVEL
Posted by CLINUVEL
March 24, 2021

Media Release - CLINUVEL Expands DNA Repair Program

SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) CLINUVEL...

Read More
CLINUVEL
Posted by CLINUVEL
March 24, 2021

SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)

CLINUVEL today announced that it has reached agreement with clinical and academic...

Read More
CLINUVEL
Posted by CLINUVEL
March 10, 2021

Investor Presentation - Daiwa Investment Conference Tokyo 2021

10 March 2021 – Melbourne, Australia On 10 March 2021 CLINUVEL presented...

Read More
CLINUVEL
Posted by CLINUVEL
March 5, 2021

Appendix 3Y Change of Director's Interest Notice

CLINUVEL PHARMACEUTICALS LTD today released the attached Appendix 3Y which relates to...

Read More
CLINUVEL
Posted by CLINUVEL
March 3, 2021

Appendix 3Y Change of Director's Interest Notice

Information or documents not available now must be given to ASX as...

Read More
We use cookies to give you the best experience.